Étiquette : Immuno-Oncology

INOVOTION

by jbertholdin Institutions, Service Providers & others

INOVOTION

About the company

Inovotion is a breakthrough in vivo platform without animal experimentation-3Rs with multiple value creation applications in Drug Discovery and Personalize Medicine.

Inovotion’s Drug Discovery solution, for anticancer drugs including Immuno-Oncology, deliver faster results, higher sensitivity, strong reliability, and very large cost savings. By eliminating low-value molecules, Inovotion accelerates the drug discovery process and significantly reduces its costs and the animal use. Inovotion has carried out over 650 in vivo studies for over 130 customers in Pharma and Biotech in Europe, USA, and Asia.


Inovotion develops new applications for Personalized Medicine, based on a unique assay to grow tumor avatars derived from patients’ Organoids, Biopsies or Circulating Tumor Cells (CTCs).
Inovotion has so far self-financed the development of its multi-function platform though a successful CRO business (over 45% growth in 2023).
Inovotion is now seeking a powerful partner to accelerate its development and disseminate throughout the Biopharma industry in USA and Europe.

About the solution

Inovotion’s Drug Discovery solution is tailored for anticancer drugs, including those in Immuno-Oncology. It provides quicker outcomes, enhanced sensitivity, exceptional reliability, and substantial cost reductions compared to traditional models. By weeding out molecules of low potential, Inovotion expedites the drug discovery journey, drastically cutting down on expenses and the need for animal testing.

Their next generation of in vivo efficacy and toxicity tests:
#EFFICACY of oncology or immuno-oncology drugs
#EARLY TOXICITY assays
#TARGET VALIDATION in oncology
#MULTI-CANCER SCREENING to (re)position
#MECHANISM OF ACTION (angiogenesis, fibrosis, immune cell infiltration, transciptomic, PK,…)
INOVOTION has also developed news assay dedicated to the evaluation of biomaterial.

Website
Key information

–  Therapeutic areas: Oncology, Immuno-Oncology

–  Based in: Gières (FRANCE)

–  Employees: 11 – 50

–  Created in: 2015

INOVARION

by jbertholdin Institutions, Service Providers & others

INOVARION

About the company

Inovarion is a Life Sciences company based in Paris offering preclinical and fundamental research services.

Since 2013, Inovarion provides support to the pharmaceutical, biotechnology industries and academics in the form of research services outsourced on a contract basis. They help biotech companies to reach clinical trials faster outsourcing their R&D to Inovarion in France.

They have been working as an extension of their partners’ teams for Sanofi, L’Oréal, Inserm (French NIH), Gustave Roussy, and many more.

About the solution

Inovarion has developed a strong expertise in bioinformatics, oncology, immunology and molecular biology.
They are well established in the research landscape in France and published +140 scientific papers in the highest ranked reviews (Nature, Science, The Lancet, Cell…).

Here are their main advantages:
⁃ Scientific French excellence
⁃ Cost effectiveness thanks to French tax credits : 25%-40% less vs US project cost
⁃ Talent loyalty & stability: less than 5% staff turnover per year in our team

Their goal is to build up close and long-term cooperation with pharmaceutical and biotechnologiy companies worldwide, to offer them in France, very attractive conditions, both financial and time-saving, for conducting top-notch fundamental and preclinical research and beyond that, to achieve together scientifical victories in medicine.

Website
Key information

–  Therapeutic areas: Immuno-oncology, Neuroscience, Dermatology, Oncology, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 51-200

–  Created in: 2013

MABSILICO

by jbertholdin Biotech, Pharma

MABSILICO

About the company

MAbSilico is the TechBio pionner company specializing in computational solutions for discovering and designing therapeutic antibodies. Their solutions leverages artificial intelligence (AI) and machine learning to characterize, optimize and design therapeutic antibodies.

MAbSilico’s platform aims to accelerate the antibody discovery process by structural design with epitope-driven and multiparametric approaches. This allows to design highly effective antibodies, saving time and resources compared to traditional methods. We provide fully characterized antibodies against a target within 21 days that are internally validated with wet lab assays, leading to faster development of life-saving antibody therapies.

About the solution

MAbSilico uses a combination of 3D modeling, interaction simulation, and sequence analysis to identify promising antibody candidates after assessing for various factors, including their binding target (epitope), affinity, potential off-target effects, and developability.

While the solutions can be applied to antibody characterization, optimization and design, MAbSilico does not need to generate biological data to apply their solutions.

Integrating multi-parameters for the antibody design and validating the newly sequence with state of the art biological assays, MAbSilico is pioneering a game-changing approach to antibody discovery with internal discovery pipeline.

Website
Key information

–  Therapeutic areas: Computational antibody design & discovery applied in oncology, Immuno-oncology, Infectious diseases, Rare diseases

–  Based in: Tours & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2017

ALTEVAX BIOTECH

by jbertholdin Biotech, Pharma

ALTEVAX BIOTECH

About the company

ALTEVAX was founded in 2016 by Professor Antoine Carpentier, neuro-oncologist and Head of the Neurology Department at Saint-Louis Hospital in Paris (AP-HP). His research on biological nanoparticles and melanin’s potential as adjuvant for vaccines resulted in a patented antigen-melanin platform technology.

Since 2016, the research team at ALTEVAX has demonstrated melanin’s ability to shield antigens from degradation and transport them to the lymph nodes, where they induce a robust and specific immune response involving CD4 and CD8. ALTEVAX technology is protected by two families of general patents and can be used in a wide range of new vaccines depending on the antigens selected.

ALTEVAX lead product, a therapeutic vaccine against Glioblastoma, based on the tumor-associated antigen TERT (from the telomerase complex), has completed the final stage of preclinical development, and will enter a Phase 1/2a clinical trial in newly diagnosed glioblastoma in Q3 2024.

About the solution

ALTEVAX technology, peptide-based vaccines using melanin as adjuvant triggers a specific immune response, involving CD4+ and CD8+ lymphocytes, against self-antigens that is more effective and faster than current vaccine technology using emulsions, RNA (primarily producing antibodies and few CD8+), or DNA as messenger vectors. Laboratory experiments confirmed its superior efficacy.

Melanin induces an immune reaction similar to the reaction by the human body when defending against pathogenic aggressions. It is a natural, non-toxic product and offers an excellent benefit-to-risk ratio.

ALTEVAX mastered the production process for synthetic melanin and its combination with peptides. Its vaccines will be administered subcutaneously, simplifying administration, and reducing costs.

Website
Key information

–  Therapeutic areas: Oncology, Therapeutic Vaccine, Immuno-Oncology, Immunotherapy, Adjuvant Platform, Glioblastoma

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2016

EXELIOM BIOSCIENCES

by jbertholdin Biotech, Pharma

EXELIOM BIOSCIENCES

About the company

Exeliom Biosciences is developing a new generation of immunotherapies based on therapeutic targets that play a critical role in our innate immunity.

Our lead candidate, EXL01, is being currently evaluated in a Phase 1 clinical trial in Crohn’s disease, and in two Phase 2 clinical trials in gastric cancer in combination with FOLFOX and nivolumab, and in the prevention of recurrent C. difficile infection as an alternative to FMT. At least three additional Phase 2 trials in immune-oncology in combination with immune-checkpoint inhibitors and in postoperative Crohn’s disease are expected to start this year.

EXL01, a single-strain (F. prausnitzii) live biotherapeutic product, carries unique effectors promoting a distinct and potent immuno-modulatory signal. EXL01 also promotes antitumor efficacy of PD-L1 therapy and can be used in combination with immune-checkpoint inhibitors.
Exeliom is pushing in parallel other candidates in its pipeline, including small molecules, acting on essential pathways of our innate immunity.

About the solution

Our lead candidate, EXL01, has unique effectors that can co-activate key targets in the innate immune response to induce tolerogenic effects without inhibiting the immune system. As a potent immunomodulator, EXL01 is more suitable for chronic administration than existing immunosuppressants currently on the market, particularly for the treatment of inflammatory bowel diseases. Interestingly, the tolerogenic effects induced by EXL01 on the innate immune system have a boosting effect on immunotherapies when administered in combination, notably in immuno-oncology. Indeed, EXL01 enables better expression of immune checkpoint receptors and therefore better target presentation for immune checkpoint inhibitors.

Website
Key information

–  Therapeutic areas: Immuno-Oncology, Inflammatory Bowel Diseases, Infectious Diseases

–  Based in: Paris, Jouy-en-Josas, Dijon (FRANCE)

–  Employees: 1 – 10

– Created in: 2016

CONTACT
Benjamin HadidaCEO

bhadida@exeliombio.com